EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Development and validation of LC–MS-based bioanalytical methods for oligonucleotide therapeutics: points to consider

Yuchen Sun, Kosuke Saito, Shin-Ichiro Nitta, Ryoya Goda, Yuki Kishino, Hisashi Fujita, Masaaki Kakehi, Yoshiharu Hayashi, Satoshi Ito, Tomomi Ishida, Kiyomi Kikuchi, Kazuko Inoue und 9 weitere

Drug Metabolism and Pharmacokinetics · 2026

DOI: 10.1016/j.dmpk.2026.101545 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2026. Verfasst von Yuchen Sun und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicinal Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa, 210-9501, Japan…. Hauptthemen laut MEDLINE: Liquid Chromatography-Mass Spectrometry, Oligonucleotides. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The analysis of oligonucleotide therapeutics, including antisense oligonucleotides and siRNAs, using existing bioanalytical methods presents unique analytical challenges owing to their distinctive physicochemical properties. Although the ICH M10 guideline provides general bioanalytical validation frameworks, specific considerations for oligonucleotide therapeutics remain undefined, highlighting an urgent need for targeted points to be considered. This white paper presents comprehensive recommendations developed through expert consensus and a literature review by the Japan Agency for Medical Research and Development research groups, addressing the critical technical challenges in liquid chromatography-mass spectrometry (LC-MS)-based bioanalytical methods for oligonucleotide therapeutics. It focuses on ion-pair reversed-phase LC-MS methodologies and emerging techniques, such as hybridization extraction, addressing key issues, including mobile phase stability and degradation, metal adsorption mitigation, carryover prevention, internal standard selection, and matrix effects unique to nucleic acids. The comprehensive coverage includes sample preparation strategies, chromatographic optimization, mass spectrometric detection approaches, and validation parameters adapted from ICH M10, with fit-for-purpose modifications on a case-by-case basis when conventional acceptance criteria cannot be applied. This white paper provides practical recommendations for the development and validation of analytical methods specific to oligonucleotide therapeutics, supports regulatory submissions, and promotes the international harmonization of bioanalytical standards in this rapidly expanding therapeutic modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liquid Chromatography-Mass SpectrometryOligonucleotidesHumansChromatography, Liquid

Stichwörter der Autor:innen

BioanalysisICH M10LC–MSMethod validationOligonucleotide therapeuticsRegulatory submissionWhite paper

Substanzen

Oligonucleotides

Autor:innen und Institutionen

  • Division of Medicinal Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa, 210-9501, Japan. Electronic address: yuchen.s@nihs.go.jp.
  • Division of Medicinal Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa, 210-9501, Japan. Electronic address: saitok2@nihs.go.jp.
  • Mediford Corporation, 1-15-10 Shimura, Itabashi-ku, Tokyo, 174-0056, Japan. Electronic address: shinichiro.nitta@mediford.com.
  • Future Peak Co., Ltd., 3-48 Imainakamachi, Nakahara-ku, Kawasaki City, Kanagawa, 211-0065, Japan. Electronic address: goda.ryoya@future-peak.co.jp.
  • Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan. Electronic address: yuki.kishino@daiichisankyo.com.
  • Takeda Pharmaceutical Co., Ltd., 2-26-1 Muraokahigashi, Fujisawa City, Kanagawa, 251-8555, Japan. Electronic address: hisashi.fujita1@takeda.com.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Sun, Y., Saito, K., Nitta, S. I., Goda, R., Kishino, Y., Fujita, H., Kakehi, M., Hayashi, Y., Ito, S., Ishida, T., Kikuchi, K., Inoue, K., Shimbo, K., Yamaguchi, T., Jinno, F., Murakoshi, K., Murata, C., Takahara, K., Kawabata, M., …, & Saito, Y. (2026). Development and validation of LC–MS-based bioanalytical methods for oligonucleotide therapeutics: points to consider. Drug Metabolism and Pharmacokinetics. https://doi.org/10.1016/j.dmpk.2026.101545

Vancouver

Sun Y, Saito K, Nitta SI, Goda R, Kishino Y, Fujita H, et al. Development and validation of LC–MS-based bioanalytical methods for oligonucleotide therapeutics: points to consider. Drug Metabolism and Pharmacokinetics. 2026. doi:10.1016/j.dmpk.2026.101545

BibTeX
@article{Sun2026,
  author = {Sun, Yuchen and Saito, Kosuke and Nitta, Shin-Ichiro and Goda, Ryoya and Kishino, Yuki and Fujita, Hisashi and Kakehi, Masaaki and Hayashi, Yoshiharu and Ito, Satoshi and Ishida, Tomomi and Kikuchi, Kiyomi and Inoue, Kazuko and Shimbo, Kazutaka and Yamaguchi, Takeru and Jinno, Fumihiro and Murakoshi, Kaori and Murata, Chie and Takahara, Kentaro and Kawabata, Mitsuhiko and Kikura-Hanajiri, Ruri and Saito, Yoshiro},
  title = {Development and validation of LC–MS-based bioanalytical methods for oligonucleotide therapeutics: points to consider},
  journal = {Drug Metabolism and Pharmacokinetics},
  year = {2026},
  doi = {10.1016/j.dmpk.2026.101545}
}
Kostenlos starten →